Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Drugs
Erschienen in: Drugs 6/2020

01.04.2020 | AdisInsight Report

Tislelizumab: First Approval

verfasst von: Arnold Lee, Susan J. Keam

Erschienen in: Drugs | Ausgabe 6/2020

Einloggen, um Zugang zu erhalten

Abstract

Tislelizumab (百泽安®;替雷利珠单抗; Tileilizhu Dankang Zhusheye) is an anti-human programmed death receptor-1 (PD-1) monoclonal IgG4 antibody that is being developed by BeiGene as an immunotherapeutic, anti-neoplastic drug. Tislelizumab has been investigated in haematological cancers and advanced solid tumours, leading to its approval in December 2019 in China for patients with relapsed or refractory classical Hodgkin’s lymphoma after at least second-line chemotherapy. This article summarises the major milestones in the development of tislelizumab for this first approval for classical Hodgkin’s lymphoma, and its potential upcoming approvals in other indications.
Literatur
1.
Chen X, Song X, Li K, et al. FcγR-binding is an important functional attribute for immune checkpoint antibodies in cancer immunotherapy. Front Immunol. 2019;10:292.CrossRef
2.
Zhang T, Song X, Xu L, et al. The binding of an anti-PD-1 antibody to FcgammaRIota has a profound impact on its biological functions. Cancer Immunol Immunother. 2018;67(7):1079–90.CrossRef
3.
BeiGene. China National Medical Products Administration approves BeiGene’s tislelizumab for patients with classical Hodgkin’s lymphoma who have received at least two prior therapies. [media release] 27 Dec 2019. http://​www.​beigene.​com.
4.
5.
6.
7.
Celgene Corporation. Celgene Corporation enters into global strategic immuno-oncology collaboration with BeiGene to advance PD-1 inhibitor program for solid tumor cancers. [media release] 5 Jul 2017. http://​www.​beigene.​com.
8.
9.
10.
BeiGene. BeiGene and Boehringer Ingelheim announce commercial supply agreement for anti-PD-1 antibody tislelizumab. [media release] 9 Jan 2018. http://​www.​beigene.​com.
11.
BioAtla, BeiGene. BioAtla and BeiGene form worldwide collaboration to develop and commercialize novel conditionally active biologic CTLA-4 therapy. [media release] 9 Apr 2019. http://​www.​beigene.​com.
12.
BeiGene. US Securities and Exchange Comission Form 10-K, BeiGene, LTD. Annual Filings. 2019.
13.
Zhang T, Song J, Li Y, et al. Antihuman PD-1 antibody BGB-A317 exhibits potent immune cell activation [abstract no. 2226]. Cancer Research Conference: 107th AACR Annual Meeting 2016;76(Suppl 14).
14.
Feng Y, Hong Y, Sun H, et al. The molecular binding mechanism of tislelizumab, an investigational anti-PD-1 antibody, is differentiated from pembrolizumab and nivolumab [abstract no. 2383]. Cancer Research Conference: AACR Annual Meeting. 2019;79(Suppl 13).
15.
Wu X, Zhang T, Fu C, et al. Activation of tumor infiltrating lymphocytes from colorectal cancer and colorectal liver metastasis patients by anti-human PD-1 antibody BGB-A317 in a 3D spheroid system [abstract no. e14560]. JCO Conference. 2016;34(Suppl 15).
16.
Luo L, Wu X, Zhang T, et al. Investigation of T cell activation by anti-human PD-1 antibodies nivolumab, pembrolizumab and BGB-A317 using tumor-infiltrating lymphocytes (TILs) from colorectal cancer and colorectal liver metastasis patients [abstract no. 5626]. AACR Annual Meeting. 2017;77(Suppl 13).
17.
Song Y, Gao Q, Zhang H, et al. Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study. Leukemia. 2019.
18.
Ye D, Liu J, Zhou A, et al. First report of efficacy and safety from a phase II trial of tislelizumab, an anti-PD-1 antibody, for the treatment of PD-L1 + locally advanced or metastatic urothelial carcinoma (UC) in Asian patients [abstract no. 920P]. Ann Oncol. 2019;30(Suppl 5):v367.
19.
BeiGene. BeiGene announces clinical results on tislelizumab presented at the 22nd Annual Meeting of the Chinese Society of Clinical Oncology (CSCO). [media release] 22 Sep 2019. http://​beigene.​com.
20.
BeiGene. BeiGene announces updated phase 1A/1B data on tislelizumab presented at the European Society for Medical Oncology Immuno-Oncology Congress. [media release] 15 Dec 2018. http://​beigene.​com.
21.
BeiGene. BeiGene announces clinical data on tislelizumab presented at European Society for Medical Oncology (ESMO) Asia 2019 Congress. [media release] 23 Nov 2019. http://​www.​beigene.​com.
22.
Deva S, Lee JS, Lin CC, et al. A phase Ia/Ib trial of tislelizumab, an anti-PD-1 antibody (ab), in patients (pts) with advanced solid tumors [abstract no. 70O]. Ann Oncol. 2018;29(Suppl 10):x33.
23.
BeiGene. BeiGene announces that the phase 3 clinical trial of its anti-PD-1 antibody tislelizumab in patients with first- line squamous non-small cell lung cancer met the primary endpoint of progression-free survival at interim analysis. [media release] 21 Jan 2020. http://​beigene.​com.
24.
25.
Tam CS, Cull G, Opat S, et al. An update on safety and preliminary efficacy of highly specific bruton tyrosine kinase (BTK) Inhibitor zanubrutinib in combination with PD-1 inhibitor tislelizumab in patients with previously treated B-Cell lymphoid malignancies. 61st ASH Annual Meeting 2019;134(Suppl 1):1594.
26.
BeiGene. BeiGene announces clinical data on investigational anti-PD-1 antibody tislelizumab in combination with sitravatinib at European Society for Medical Oncology Immuno-Oncology (ESMO I-O) Congress 2019. [media release] 13 Dec 2019. http://​beigene.​com.
27.
Friedlander M, Meniawy T, Markman B, et al. Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial. Lancet Oncol. 2019;20(9):1306–15.CrossRef
28.
Meniawy T, Richardson G, Townsend A, et al. Preliminary results from a subset of patients (pts) with advanced ovarian cancer (OC) in a dose-escalation/expansion study of BGB-A317, an anti-PD-1 monoclonal antibody (mAb) [abstract no. 389P]. Ann Oncol. 2017;28(Suppl 5):v130.
29.
Desai J, Markman B, Friedlander M, et al. Long-term exposure (LTE) to tislelizumab, an investigational anti-PD-1 antibody, in a first-in-human phase I study [abstract no. CT084]. AACR Annual Meeting. 2019;79(Suppl 13).
30.
BeiGene. BeiGene announces acceptance of New Drug Application for anti-PD-1 antibody tislelizumab in Hodgkins lymphoma in China. [media release] 31 Aug 2018. http://​beigene.​com.
31.
BeiGene. Priority review granted to BeiGene's New Drug Applications for zanubrutinib and tislelizumab in China. [media release] 15 Nov 2018. http://​beigene.​com.
32.
BeiGene. Priority review granted to BeiGenes supplemental New Drug Application in China for tislelizumab in urothelial carcinoma. [media release] 7 Jul 2019. http://​beigene.​com.
33.
BeiGene. BeiGene announces acceptance of a supplemental New Drug Application in China for tislelizumab in urothelial carcinoma. [media release] 30 May 2019. http://​www.​beigene.​com.
Metadaten
Titel
Tislelizumab: First Approval
verfasst von
Arnold Lee
Susan J. Keam
Publikationsdatum
01.04.2020
Verlag
Springer International Publishing
Erschienen in
Drugs / Ausgabe 6/2020
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI
https://doi.org/10.1007/s40265-020-01286-z

Weitere Artikel der Ausgabe 6/2020

Drugs 6/2020 Zur Ausgabe

AdisInsight Report

Delgocitinib: First Approval

AdisInsight Report

Remimazolam: First Approval

Leading Article

Targeted Treatment for Erythrodermic Psoriasis: Rationale and Recent Advances

Leading Article

Advances in Long-Acting Agents for the Treatment of HIV Infection

Original Research Article

Efficacy and Safety of Remogliflozin Etabonate, a New Sodium Glucose Co-Transporter-2 Inhibitor, in Patients with Type 2 Diabetes Mellitus: A 24-Week, Randomized, Double-Blind, Active-Controlled Trial

Review Article

A Review of Management Strategies for Nociceptive and Neuropathic Ocular Surface Pain